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
私たちのソリューション
私たちは、医薬品の開発、分析サービス、フェーズI〜IVの医薬品臨床試験、医薬品・医療機器・食品・化粧品に関する薬事関連業務、安全性情報管理業務、さらに、これら業務に関するドキュメント作成、翻訳等のサービスも提供しています。
NEws and events
-
Meet our people: CRA ensuring success of clinical trials
01.02.2023
カテゴリーなし
-
Client story: Medfiles offers indispensable support to Oriflame in food supplement labelling texts
31.01.2023
カテゴリーなし
-
Medfiles expands its operations to Sweden
19.01.2023
カテゴリーなし
-
CTIS soon the single entry point for submitting clinical trials in the EU
16.01.2023
カテゴリーなし
-
Free Guide: What you need to know about active substance registration strategy?
12.01.2023
カテゴリーなし
-
Extended transitional periods for MDR released by EU Commission
11.01.2023
カテゴリーなし
